First investment tranche for DNA ERA signed. The campaign continues.

The Slovak biotechnology startup DNA ERA has built an established position in the field of genetic analysis and DNA testing within the Czech and Slovak market. The company plans to expand into new markets and innovate its portfolio of products and services, for which it plans to use the capital from Crowdberry investors. The first investment tranche, with a target amount of EUR 1 million, was signed at the beginning of June. The investment fund managed by CB Investment Management also participated.

The DNA ERA company is focusing on direct genetic analysis of DNA using proprietary software and an interactive application for data interpretation. Thanks to this, it can help to detect predispositions to diseases, genetic risks or to find out sports potential. After an initial investment of EUR 250 thousand from an investment fund CB Growth ONE in 2020, DNA ERA has managed to successfully enter the Czech market and launch new products and services. The company ended 2021 with a turnover of EUR 684 thousand and a year-on-year revenue growth of more than 700%. 

DNA ERA is following the positive trend even this year. To further accelerate its growth strategy, it has launched an investment campaign in cooperation with Crowdberry to raise capital from private investors in March this year. "We see the capital in the form of new investment as a stepping stone on the way to further expanding our product portfolio. In addition, backed by investors from the Crowdberry platform, we will focus on offering new tests and a modern personalized approach to prevention and health. Later this year we plan to enter a new market and offer DNA tests in local language and with local support also in Poland," says CEO and founder of the company, Michaela Šišková.

The potential of this part of the biotechnology industry is confirmed by the value of global market for genetic testing, which reached  EUR 7 billion in 2021 – and is expected to grow at an average annual rate of 7.6% until 2030, reaching almost EUR 14 billion (source: Globenewswire). In Slovakia, DNA ERA is a pioneer in this field and its business as well as scientific potential is appreciated by Pavol Čekan, its expert guarantor: